Pace David
Department of Paediatrics, Mater Dei Hospital, Tal-Qroqq, Msida, Malta.
Expert Rev Vaccines. 2009 May;8(5):529-42. doi: 10.1586/erv.09.18.
Invasive meningococcal disease is a global public-health concern, with infants and adolescents bearing the majority of the disease burden. Vaccination is the most rational strategy to prevent meningococcal disease. Control of serogroup C disease has largely been achieved by the introduction of glycoconjugate meningococcal C vaccines, initially in the UK in 1999, and subsequently in several other countries. The recent licensure of a quadrivalent glycoconjugate vaccine against serogroups A, C, Y and W-135 in the USA and Canada has broadened protection against Neisseria meningitidis in 2-55 year olds. The investigational quadrivalent meningococcal serogroup A, C, Y and W-135 glycoconjugate vaccine (MenACYW-CRM197), which is immunogenic from infancy, has the potential to extend protection to the most vulnerable age group. This article discusses this novel quadrivalent vaccine formulation and its potential to control invasive disease caused by N. meningitidis serogroups A, C, Y and W-135.
侵袭性脑膜炎球菌病是一个全球公共卫生问题，疾病负担主要落在婴儿和青少年身上。接种疫苗是预防脑膜炎球菌病最合理的策略。通过引入糖共轭脑膜炎球菌C疫苗，C群疾病的控制已基本实现，该疫苗最初于1999年在英国使用，随后在其他几个国家也开始使用。最近，一种针对A、C、Y和W-135群的四价糖共轭疫苗在美国和加拿大获得许可，扩大了对2至55岁人群针对脑膜炎奈瑟菌的保护范围。正在进行研究的四价A、C、Y和W-135群脑膜炎球菌糖共轭疫苗（MenACYW-CRM197）在婴儿期即具有免疫原性，有可能将保护范围扩大到最脆弱的年龄组。本文讨论了这种新型四价疫苗制剂及其控制由A、C、Y和W-135群脑膜炎奈瑟菌引起的侵袭性疾病的潜力。
